Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Oncology
Oncology · The big question

One protein predicts opposite outcomes in breast and ovarian cancers

DHX37 protein and mRNA expression patterns in breast and ovarian cancer and their prognostic implications.

PubMed2 min readAI-assisted summary
Editorial illustration for DHX37 protein and mRNA expression patterns in breast and ovarian cancer and their prognostic implications.
Editorial illustration

Summary

Inside our cells, a protein called DHX37 helps manage how genetic instructions are read and how the immune system behaves. Because molecular mix-ups often lead to cancer, scientists recently set out to see if the levels of this specific protein could tell us anything about how tumors grow. To find out, they analyzed tissue samples from a large group of patients, looking at more than 1,500 breast cancer cases and 420 ovarian cancer cases.

The results revealed a fascinating biological plot twist. The protein behaves completely differently depending on the type of cancer. In breast cancer, having low levels of DHX37 is a troubling sign. It correlates with larger tumors, more aggressive disease, and poorer survival rates, especially for patients with estrogen receptor-positive breast cancer. However, in ovarian cancer, low levels of the exact same protein are a positive sign. For these patients, low DHX37 is linked to earlier stages of the disease, a lack of leftover tumor tissue after treatment, and better overall survival.

While these contrasting patterns are striking, the researchers note important caveats. This was strictly an observational study, meaning scientists looked at existing tumor samples and patient outcomes without testing how the protein actually works in a living system. Further research is required to understand the actual mechanics of why DHX37 might encourage tumor growth in one environment while being linked to favorable outcomes in another.

Why it matters.

Modern cancer care relies heavily on prognostic biomarkers, which are biological clues that help doctors predict how a patient's disease might progress. If further testing confirms these results, DHX37 could become a helpful tool in the oncology clinic. For the massive population of breast cancer patients, particularly those with the very common estrogen receptor-positive subtype, a test for this protein could help doctors spot aggressive tumors early and adjust treatment plans accordingly.

Conversely, ovarian cancer is notoriously difficult to catch early and treat effectively. Having a reliable indicator of a favorable outcome could help doctors make better decisions about how intensely to treat a patient. Beyond immediate clinical testing, unraveling the mystery of how one protein can play opposing roles in different reproductive cancers could eventually point researchers toward entirely new drug targets in the future of cancer medicine.

From the source

The story in numbers.

Breast cancer cases analyzed
1512
Ovarian cancer cases analyzed
420
Significance of association between low DHX37 and poor survival in breast cancer
P < 0.001
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Oncology

Targeted Drug Spares Lymphoma Patients from Stem Cell Transplants

Mantle cell lymphoma is a challenging type of blood cancer. For years, the standard treatment for younger, relatively fit patients has been a heavy dose of chemotherapy followed by an autologous stem cell transplant. This transplant process involves collecting a patient's own healthy stem cells, delivering high-dose chemotherapy to wipe out the cancer, and then returning the healthy cells to help the body recover. It is an intense procedure that can be incredibly hard on the body. A recent major clinical trial followed 870 patients across Europe and Israel for over four years to see if adding a targeted daily pill called ibrutinib could improve outcomes. Researchers split the patients into three groups to test different combinations of standard chemotherapy, ibrutinib, and stem cell transplants. They found that adding ibrutinib significantly boosted both how long patients lived overall and how long they lived without their cancer returning or worsening. The most welcome discovery was that the grueling stem cell transplant may no longer be necessary. The group that received chemotherapy and ibrutinib but skipped the transplant did just as well as the group that received all three. Adding the transplant to the ibrutinib regimen provided no extra survival benefit but significantly increased the risk of severe side effects, like dangerous drops in healthy blood cells. It is worth noting that this study only looked at untreated patients aged 18 to 65, so the findings might not apply to older or less fit individuals.

PubMed2 min read
Oncology

Colorectal Cancer Prepares to Spread Earlier Than We Thought

For anyone diagnosed with cancer, the most dangerous moment is when the disease begins to spread to new areas of the body, a process known as metastasis. Scientists have long wondered exactly when and how a localized tumor gains the ability to travel. In a new study looking at colorectal cancer, researchers made a surprising discovery. They found that tumors actually develop the necessary tools to spread much earlier than previously believed. By studying patient samples and miniature lab-grown tumors called organoids, the research team looked at how tumor cells behave at a microscopic level. They discovered that many early-stage tumors adopt a highly flexible condition called an oncofetal state. Normally, this shapeshifting ability is only seen in advanced, late-stage cancers. But the researchers found that these flexible cancer cells were already gathering at the edges of early tumors. There, they mingle with normal connective tissue cells known as fibroblasts, which actively encourage the cancer cells to become even more adaptable and ready to move. However, simply having these flexible cells is not enough to guarantee the cancer will spread, since not all early-stage tumors actually go on to metastasize. The researchers investigated what pushes the tumor over the edge. They ruled out new genetic mutations as the trigger. Instead, their findings suggest that a cancer cell's ability to hide from the immune system might be the final key to unlocking its deadly spread.

Nature Genetics2 min read
Oncology

New nanoparticle tech breaks down tumor shields to boost immunity

Tumors have a sneaky way of hiding from the body's immune system. They wrap themselves in a dense, sugary protective coating known as the glycocalyx. This shield is packed with mucins, which are thick proteins that physically block immune cells and modern cancer treatments from reaching the target. While scientists have discovered a bacterial enzyme called StcE that can chew through this sticky barrier, using it as a drug has been difficult. Injecting the free enzyme directly into the body causes unwanted toxic side effects and triggers severe immune reactions. To solve this problem, researchers engineered a clever delivery system using cell membrane fusion nanovesicles, which are essentially microscopic bubbles made from natural cell materials. They equipped these tiny delivery vehicles with both the barrier-breaking StcE enzyme and specialized targeting molecules called CD47 nanobodies. These nanobodies act like a homing device that seeks out cancer cells. By using this biomimetic delivery platform, the enzyme successfully digests the protective sugary shield precisely at the tumor site, avoiding the widespread toxicity and safety issues of the free enzyme. With the barrier cleared away, the immune system gets a much clearer shot at the tumor. The researchers found that removing the mucin shield allowed the nanobodies to bind tightly to the cancer cells, sounding the alarm for the body's natural defenses. The treatment successfully suppressed tumor growth and stopped the cancer from spreading by radically remodeling the environment around the tumor, bringing in a flood of protective immune cells.

PubMed2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗
One protein predicts opposite outcomes in breast and ovarian cancers — Daily Strand